Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pamela Biondani

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Tumori|June 9, 2012
Management of advanced genitourinary tumorsFilippo Pietrantonio, Pamela Biondani, Elena Verzoni, et al.
Tumori|June 9, 2012
New perspectives in advanced genitourinary malignanciesPamela Biondani, Giuseppe Procopio, Filippo Pietrantonio, et al.
Anticancer Research|October 3, 2014
Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinomaEmilio Bajetta, Laura Catena, Pamela Biondani, et al.
Tumori|March 29, 2014
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastasesGiuseppe Procopio, Elena Verzoni, Pamela Biondani, et al.
Medical Oncology (Northwood, London, England)|January 25, 2012
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumabFilippo Pietrantonio, Pamela Biondani, Alessandro Pellegrinelli, et al.
Pharmacogenomics and Personalized Medicine|April 10, 2014
Targeted treatments in advanced renal cell carcinoma: focus on axitinibElena Verzoni, Paolo Grassi, Isabella Testa, et al.
Anticancer Research|April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patientsPamela Biondani, Elena Verzoni, Valter Torri, et al.
Translational Oncology|June 29, 2012
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimenFilippo Pietrantonio, Pamela Biondani, Filippo de Braud, et al.
BMC Cancer|June 5, 2020
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancerAyhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, et al.
Medicine|April 23, 2019
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinomaAyhan Ulusakarya, Nahla Teyar, Abdoulaye Karaboué, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Tumori|June 9, 2012
Management of advanced genitourinary tumorsFilippo Pietrantonio, Pamela Biondani, Elena Verzoni, et al.
Tumori|June 9, 2012
New perspectives in advanced genitourinary malignanciesPamela Biondani, Giuseppe Procopio, Filippo Pietrantonio, et al.
Anticancer Research|October 3, 2014
Activity of a three-drug combination including cisplatin (CLOVER regimen) for poorly differentiated neuroendocrine carcinomaEmilio Bajetta, Laura Catena, Pamela Biondani, et al.
Tumori|March 29, 2014
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastasesGiuseppe Procopio, Elena Verzoni, Pamela Biondani, et al.
Medical Oncology (Northwood, London, England)|January 25, 2012
Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumabFilippo Pietrantonio, Pamela Biondani, Alessandro Pellegrinelli, et al.
Pharmacogenomics and Personalized Medicine|April 10, 2014
Targeted treatments in advanced renal cell carcinoma: focus on axitinibElena Verzoni, Paolo Grassi, Isabella Testa, et al.
Anticancer Research|April 30, 2014
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patientsPamela Biondani, Elena Verzoni, Valter Torri, et al.
Translational Oncology|June 29, 2012
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimenFilippo Pietrantonio, Pamela Biondani, Filippo de Braud, et al.
BMC Cancer|June 5, 2020
A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancerAyhan Ulusakarya, Abdoulaye Karaboué, Oriana Ciacio, et al.
Medicine|April 23, 2019
Patient-tailored FOLFIRINOX as first line treatment of patients with advanced pancreatic adenocarcinomaAyhan Ulusakarya, Nahla Teyar, Abdoulaye Karaboué, et al.
Pageof 3